These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 23711183)
21. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes. Aoyama K; Kamio T; Nishikawa T; Kameoka S Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990 [TBL] [Abstract][Full Text] [Related]
22. Is cytology reliable for epidermal growth factor receptor gene evaluation in non-small cell lung cancer? Bozzetti C; Tiseo M; Lagrasta C; Nizzoli R; Guazzi A; Graiani G; Rindi G; Ardizzoni A J Thorac Oncol; 2010 Apr; 5(4):551-3. PubMed ID: 20357620 [TBL] [Abstract][Full Text] [Related]
23. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065 [TBL] [Abstract][Full Text] [Related]
24. [Detection of epidermal growth factor receptor gene amplification in human laryngeal carcinomas by means of fluorescence in situ hybridization]. Li F; Kang N; Fu W; Sun X; Gao H; Sun K Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Aug; 17(4):278-80. PubMed ID: 10932015 [TBL] [Abstract][Full Text] [Related]
25. Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas. Fischer C; Zlobec I; Stöckli E; Probst S; Storck C; Tornillo L; Lugli A; Wolfensberger M; Terracciano L Hum Pathol; 2008 Oct; 39(10):1527-34. PubMed ID: 18620726 [TBL] [Abstract][Full Text] [Related]
26. The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines. Long TH; Lawce H; Durum C; Moore SR; Olson SB; Gatter K; Troxell ML Am J Clin Pathol; 2015 Aug; 144(2):253-62. PubMed ID: 26185310 [TBL] [Abstract][Full Text] [Related]
27. Fluorescence in situ hybridization in cancer and radiation biology. Gray JW; Pinkel D; Brown JM Radiat Res; 1994 Mar; 137(3):275-89. PubMed ID: 8146269 [TBL] [Abstract][Full Text] [Related]
28. [Epidermal growth factor receptor family and targeted anticancer therapy]. Liu TH Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):577-9. PubMed ID: 17134561 [No Abstract] [Full Text] [Related]
29. Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas. Piris A; Scopsi L; Clemente C; Cetti Serbelloni F; Mihm MC; Hoang MP Am J Dermatopathol; 2010 Aug; 32(6):586-92. PubMed ID: 20534988 [TBL] [Abstract][Full Text] [Related]
30. Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations? Johnson BE; Jänne PA J Clin Oncol; 2005 Oct; 23(28):6813-6. PubMed ID: 16145056 [No Abstract] [Full Text] [Related]
31. Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybridization impact on prognosis in breast cancer. Li J; Su W; Zhang S; Hu Y; Liu J; Zhang X; Bai J; Yuan W; Hu L; Cheng T; Zetterberg A; Lei Z; Zhang J Cancer Sci; 2015 May; 106(5):642-9. PubMed ID: 25702787 [TBL] [Abstract][Full Text] [Related]
32. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Sauter G; Maeda T; Waldman FM; Davis RL; Feuerstein BG Am J Pathol; 1996 Apr; 148(4):1047-53. PubMed ID: 8644846 [TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Buckley AF; Burgart LJ; Kakar S Hum Pathol; 2006 Apr; 37(4):410-4. PubMed ID: 16564914 [TBL] [Abstract][Full Text] [Related]
34. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628 [TBL] [Abstract][Full Text] [Related]
35. [Report of the working group on molecular pathology. Minutes of the members meeting held as part of the 96th annual meeting of the DGP in Berlin]. Dietmaier W; Arens N; Haller F Pathologe; 2012 Nov; 33 Suppl 2():344-6. PubMed ID: 23011026 [No Abstract] [Full Text] [Related]
37. Common Fluorescence In Situ Hybridization Applications in Cytology. Savic S; Bubendorf L Arch Pathol Lab Med; 2016 Dec; 140(12):1323-1330. PubMed ID: 27479335 [TBL] [Abstract][Full Text] [Related]
38. In vivo fluorescence imaging for cancer diagnosis using receptor-targeted epidermal growth factor-based nanoprobe. Ryu JH; Shin M; Kim SA; Lee S; Kim H; Koo H; Kim BS; Song HK; Kim SH; Choi K; Kwon IC; Jeon H; Kim K Biomaterials; 2013 Dec; 34(36):9149-59. PubMed ID: 23998858 [TBL] [Abstract][Full Text] [Related]
39. Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing? Personeni N J Clin Oncol; 2007 Mar; 25(7):910; author reply 911. PubMed ID: 17327617 [No Abstract] [Full Text] [Related]
40. DNA in situ hybridization as an adjunct in tumor diagnosis. Fletcher JA Am J Clin Pathol; 1999 Jul; 112(1 Suppl 1):S11-8. PubMed ID: 10396297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]